При постмаркетинговом применении пр

При постмаркетинговом применении препарата сообщалось о кетоацидозе, в том числе диабетическом кетоацидозе, у пациентов сахарным диабетом 1 и 2 типа, принимающих препарат Форсига и другие ингибиторы SGLT-2, хотя причинно-следственная связь не была установлена.

Результаты (английский) 1:

When postmarketingovom the drug reported ketoatsidoze, including Diabetic Ketoacidosis, diabetic patients 1 and 2 type drug makers Forsiga and SGLT-2 inhibitors, although a causal relationship has not been established.

Результаты (английский) 2:

In post-marketing use of the drug reported ketoacidosis, including diabetic ketoacidosis, in patients with diabetes mellitus type 1 and 2, taking the drug Forsiga and other inhibitors of an SGLT-2, although a causal relationship has not been established.

Результаты (английский) 3:

the application of the drug кетоацидозе постмаркетинговом were reported, including диабетическом кетоацидозе, in patients with diabetes type 1 and 2, receiving the drug форсига and other inhibitors SGLT - 2, although a causal link has not been established.